NYSE:PRGO
PERRIGO Co plc
A global leader in healthcare contract manufacturing specializing in sterile injectables, OTC products, and custom development for pharmaceutical partners.
Key Metrics
Investment Thesis
Bull Case
Perrigo offers exposure to the growing global healthcare manufacturing sector with a diversified portfolio that provides resilience against single-product failures. The company's strong cash flow from operations of $238.5M and substantial goodwill suggest established market positioning and potential for future margin expansion as new product lines come online. Strategic partnerships with major pharma companies could unlock growth opportunities in complex sterile injectables, a high-growth niche within the manufacturing space.
Bear Case
The persistent negative net income trend, dropping from -$12.7M in 2023 to -$1.43B in 2025, signals severe structural profitability issues that may require years to resolve. High levels of current liabilities at $1.01B against only $2.80B in current assets indicate potential liquidity constraints and reliance on working capital cycles to fund operations. The significant debt burden with long-term debt of $3.60B and recent financing cash outflows of -$220.5M raises concerns about the company's ability to service obligations during periods of low revenue growth.
About PERRIGO Co plc
Perrigo Co plc is a global contract manufacturing and product development company serving the healthcare markets with over-the-counter consumer goods, sterile injectables, and pharmaceuticals. The company leverages its extensive network of manufacturing facilities to provide innovative solutions for major pharmaceutical partners and direct-to-consumer brands. Perrigo operates primarily in North America, Europe, Asia-Pacific, and Latin America, focusing on high-margin contract services alongside its own proprietary product portfolio.
Analysis
Management Discussion
Despite generating $4.25B in revenue, the company reported a significant net loss of -$1.43B, driven by high operating expenses of $2.62B and non-cash adjustments totaling $1.62B. The decline in revenue from $4.66B in 2023 to $4.25B in 2025 suggests a challenging macroeconomic environment or pricing pressures affecting the OTC segment, while the widening net income deficit indicates deteriorating profitability trends over the last two years.
Industry Overview
The healthcare contract manufacturing industry is characterized by high barriers to entry due to stringent regulatory requirements and the capital-intensive nature of sterile manufacturing facilities. Companies in this sector are increasingly competing on service breadth, speed-to-market, and cost efficiency as pharmaceutical companies seek to outsource more complex therapies. Market consolidation is expected to continue as smaller players struggle with compliance costs and pricing pressures from large payers.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $4.45B | $4.66B | $4.37B | $4.25B |
| Cost of Revenue | $3.00B | $2.98B | $2.83B | $2.76B |
| Gross Profit | $1.46B | $1.68B | $1.54B | $1.49B |
| Operating Expenses | $1.38B | $1.53B | $1.43B | $2.62B |
| Operating Income | $78.9M | $151.9M | $112.9M | $-1.12B |
| R&D | $123.1M | $122.5M | $112.2M | $95.4M |
| G&A | $512.3M | $522.3M | $468.0M | $435.9M |
| Marketing | $584.8M | $641.8M | $546.6M | $526.5M |
| Stock-Based Comp | $54.9M | $68.8M | $64.4M | $54.6M |
| D&A | $338.6M | $359.5M | $325.9M | $337.5M |
| Depreciation | $86.2M | $93.7M | $97.4M | $114.8M |
| Amortization | $252.4M | $265.8M | $228.5M | $222.7M |
| Other OpEx | $156.3M | $241.9M | $303.0M | $1.56B |
| Non-Operating Income | $-291.7M | $-160.2M | $-193.6M | $-175.7M |
| Pre-Tax Income | $-212.8M | $-8.3M | $-80.7M | $-1.30B |
| Income Tax | $-8.2M | $-3.9M | $80.0M | $104.4M |
| Continuing Ops | $-130.9M | $-4.4M | $-160.7M | $-1.40B |
| Discontinued Ops | $-9.7M | $-8.3M | $-11.1M | $-23.1M |
| Net Income | $-140.6M | $-12.7M | $-171.8M | $-1.43B |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-140.6M | $-12.7M | $-171.8M | $-1.43B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $2.72B | $2.83B | $2.48B | $2.80B |
| Cash & Equivalents | $600.7M | — | — | — |
| Accounts Receivable | $697.1M | $739.6M | $642.3M | $612.8M |
| Inventory | $1.15B | $1.14B | $1.08B | $1.15B |
| Prepaid Expenses | $271.8M | $201.1M | $199.0M | $231.4M |
| Other Current Assets | $0 | $751.3M | $558.8M | $804.2M |
| Long-Term Assets | $8.30B | $7.98B | $7.17B | $5.74B |
| PP&E (Net) | $926.3M | $916.4M | $917.8M | $898.7M |
| Intangibles | $5.01B | $5.00B | $4.50B | $4.76B |
| Goodwill | $3.49B | $3.53B | $3.32B | $2.05B |
| Operating Leases | $217.1M | $183.6M | $175.2M | $167.8M |
| Other LT Assets | $-1.34B | $-1.66B | $-1.75B | $-2.16B |
| Total Assets | $11.02B | $10.81B | $9.65B | $8.54B |
| Current Liabilities | $1.11B | $1.59B | $1.04B | $1.01B |
| Accounts Payable | $537.3M | $477.7M | $495.2M | $474.5M |
| Current Debt | $36.2M | $440.6M | $36.4M | $36.6M |
| Current Leases | $28.4M | $27.5M | $27.8M | $25.7M |
| Taxes Payable | $14.4M | $42.1M | $17.4M | $20.8M |
| Other Current Liab | $247.1M | $263.0M | $467.4M | $455.3M |
| Long-Term Liabilities | $5.06B | $4.45B | $4.28B | $4.59B |
| Long-Term Debt | $4.07B | $3.63B | $3.58B | $3.60B |
| LT Operating Leases | $189.5M | $159.6M | $153.8M | $151.5M |
| Other LT Liab | $801.7M | $662.5M | $548.6M | $831.7M |
| Total Liabilities | $6.18B | $6.04B | $5.33B | $5.60B |
| Shareholders' Equity | $4.84B | $4.77B | $4.32B | $2.94B |
| Retained Earnings | $-2.07B | $-2.08B | $-2.25B | $-3.68B |
| AOCI | $-27.0M | $10.7M | $-162.4M | $4.8M |
| Total L&E | $11.02B | $10.81B | $9.65B | $8.54B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-140.6M | $-12.7M | $-171.8M | $-1.43B |
| Non-Cash Adjustments | $428.1M | $528.0M | $681.1M | $1.62B |
| Working Capital Changes | $19.8M | $-109.8M | $-146.4M | $44.0M |
| Cash from Operations | $307.3M | $405.5M | $362.9M | $238.5M |
| Capital Expenditures | $96.4M | $101.7M | $118.3M | $93.4M |
| Cash from Investing | $-1.96B | $-77.5M | $78.8M | $-75.4M |
| Debt Issuances | $1.59B | $295.1M | $1.09B | $0 |
| Debt Repayments | $958.9M | $325.3M | $1.53B | $34.8M |
| Share Buybacks | $0 | — | — | — |
| Dividends Paid | $142.4M | $149.7M | $152.5M | $159.3M |
| Cash from Financing | $421.6M | $-187.2M | $-611.0M | $-220.5M |
| FX Effect | $-48.9M | $9.8M | $-23.2M | $32.5M |
| Net Change in Cash | $-1.28B | $150.6M | $-192.5M | $-24.9M |
| Beginning Cash | $1.86B | $600.7M | $751.3M | $558.8M |
| Ending Cash | $600.7M | $751.3M | $558.8M | $531.6M |
Frequently Asked Questions
How does PERRIGO Co plc make money?
The company's revenue is driven by three primary streams: Contract Manufacturing Services (CFS) providing sterile injectables, oral solids, and complex formulations; Over-the-Counter (OTC) consumer goods including vitamins and supplements sold under various brands; and Pharmaceutical Development offering custom manufacturing and clinical development services to biopharma clients.
What are the main risks for PRGO?
The company faces significant headwinds from margin compression due to intense price competition in the OTC market and potential erosion of contract manufacturing pricing power. Regulatory changes, including evolving Good Manufacturing Practices (GMP) and environmental regulations, pose compliance risks that could increase operational costs or lead to facility shutdowns. A heavy reliance on a concentrated client base for contract revenue creates vulnerability to losing major partnerships or facing payment delays from third-party payers.
What is PRGO's competitive advantage?
Perrigo maintains a robust competitive moat through its extensive global network of state-of-the-art manufacturing facilities, which provides significant scale and cost efficiencies. The company benefits from deep client relationships with major pharmaceutical partners who rely on Perrigo for complex sterile injectable capabilities that require specialized infrastructure. Additionally, Perrigo's diversified revenue stream across contract services, OTC, and development phases mitigates the impact of demand fluctuations in any single therapeutic area.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.